Literature DB >> 30485467

Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.

Julien Sitte1, Emilia Frentiu2, Cédric Baumann3, Hélène Rousseau3, Thierry May2, Jean-Pierre Bronowicki1, Laurent Peyrin-Biroulet1, Anthony Lopez1.   

Abstract

BACKGROUND: Although influenza and pneumococcal vaccinations for high-risk populations are recommended by current guidelines, vaccination coverage is low in patients with gastrointestinal cancer (GC) or inflammatory bowel disease (IBD). AIM: To evaluate the impact of a specialised infectious disease consultation on vaccination coverage rates in these patients.
METHODS: Between December 2016 and April 2017, all patients with GC or IBD followed in the outpatient clinic of the Gastroenterology department at the Nancy University Hospital enrolled in a 3-phase vaccination programme. Phase 1: Initial questionnaire (vaccination status, knowledge about vaccines and possible barriers to vaccination); Phase 2: Infectious disease consultation; Phase 3: Subsequent questionnaire (evolution of patients' knowledge about vaccination).
RESULTS: A total of 366 patients were included (GC = 99, IBD = 267). Vaccination rate was 34.7% for influenza and 14.5% for pneumococcus. About 43% of the patients feared side effects of vaccines. After the initial questionnaire, 49.3% of the interested patients participated in a specialised vaccination consultation (n = 102). 87.3% (n = 89) received new vaccination, 41.2% changed their mind about vaccination, and 92.2% would recommend this programme to other patients. Among vaccinated patients, 97.8% (n = 87) received pneumococcal vaccine, 40.4% received tetanus-diphtheria-polio vaccine, and 7.9% received influenza vaccine. In GC patients, anti-pneumococcal vaccination rate was 87.5% after the specialised consultation compared with 10.1% before. In IBD patients, corresponding rates were 85.7% and 16.1%.
CONCLUSIONS: A specialised infectious disease consultation can improve GC and IBD patients' knowledge about vaccination and vaccination coverage. This approach could be applied to all high-risk populations.
© 2018 John Wiley & Sons Ltd.

Entities:  

Year:  2018        PMID: 30485467     DOI: 10.1111/apt.15057

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey.

Authors:  Bénédicte Caron; Elise Neuville; Laurent Peyrin-Biroulet
Journal:  Dig Dis Sci       Date:  2021-05-12       Impact factor: 3.487

2.  Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.

Authors:  Claire Dupuis; Ayman Sabra; Juliette Patrier; Gwendoline Chaize; Amine Saighi; Céline Féger; Alexandre Vainchtock; Jacques Gaillat; Jean-François Timsit
Journal:  Crit Care       Date:  2021-01-10       Impact factor: 9.097

3.  COVID-19 quarantine measures are associated with negative social impacts and compromised follow-up care in patients with inflammatory bowel disease in Brazil.

Authors:  Marley Ribeiro Feitosa; Rogério Serafim Parra; Hugo Parra de Camargo; Sandro da Costa Ferreira; Luiz Ernesto de Almeida Troncon; José Joaquim Ribeiro da Rocha; Omar Féres
Journal:  Ann Gastroenterol       Date:  2020-11-26

4.  A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease.

Authors:  Guillaume Le Cosquer; Lionel Grangeon; Pauline Rivière; Arthur Berger; Frank Zerbib; David Laharie; Florian Poullenot
Journal:  Therap Adv Gastroenterol       Date:  2022-04-20       Impact factor: 4.802

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.